Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Trovagene Investor Presentation - HC Wainwright Investor Conference
 September 10, 2019 -
December 10, 2019
 10:50am EDT

Dr. Thomas Adams, CEO and Chairman and Dr. Mark Erlancer, CSO, will present an overview of Trovagene and the Onvansertib Clinical Development Program at the HC Wainwright Conference in NYC on Tuesday, September 10, at 10:50 am EDT.  The webcast of the presentation will be archived and available for 90 days.